Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells - Summary - MDSpire

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells

  • By

  • Simon M. Krauß

  • Konstantin Weibl

  • Enrica Bach

  • Mandy Brückner

  • Anne Weigert

  • Theresa Tumewu

  • Elena Ruschpler

  • Gunhild Vogtmann

  • Sandra Hoffmann

  • Olaf Penack

  • Martin Janz

  • Raymund Buhmann

  • Reinhard Henschler

  • Lars Bullinger

  • Ulrich Keller

  • Sebastian Schwind

  • Maximilian Merz

  • Madlen Jentzsch

  • Georg-Nikolaus Franke

  • Marco Herling

  • Uwe Platzbecker

  • Klaus H. Metzeler

  • Vladan Vučinić

  • June 3, 2026

  • 0 min

Share

Objective:

To evaluate the influence of clonal hematopoiesis (CH) on the manufacturing success of CAR T-cells in a cohort of patients scheduled for treatment with tisa-cel.

Key Findings:
  • CH mutations were present in 50% of successful collections, 57% of terminations, and 25% of OOS products.
  • No significant association was found between CH status and manufacturing success or proliferation-related failures.
  • The most frequently mutated genes were DNMT3A (24%), PPM1D (22%), and TET2 (18%).
Interpretation:

Remove this section.

Limitations:
  • Limited cohort size may restrict the generalizability of findings.
  • Absence of association with DNA damage response mutations does not exclude potential biological effects.
Conclusion:

Revise to eliminate unsupported claims and focus on findings.

Original Source(s)

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells

  • by Simon M. Krauß, Konstantin Weibl, Enrica Bach, Mandy Brückner, Anne Weigert, Theresa Tumewu, Elena Ruschpler, Gunhild Vogtmann, Sandra Hoffmann, Olaf Penack, Martin Janz, Raymund Buhmann, Reinhard Henschler, Lars Bullinger, Ulrich Keller, Sebastian Schwind, Maximilian Merz, Madlen Jentzsch, Georg-Nikolaus Franke, Marco Herling, Uwe Platzbecker, Klaus H. Metzeler, Vladan Vučinić

  • June 3, 2026

Related Content

Does Revolution Medicines’ pancreatic cancer drug have even greater potential?

Comprehensive Cancer Care for the Doral Community

Baptist Health Cancer Care is now serving patients in Doral with a comprehensive, community-based approach to oncology care designed to make treatment more convenient and accessible for both patients and referring physicians.

  • by

  • June 2, 2026

  • 2 min
Predicting survival in oral squamous cell carcinoma via integrated analysis of tumor budding and tertiary lymphoid structures